---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-006124"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:11:08.267121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kymera reports $850M cash, outlines 2025 pipeline milestones for KT-621, KT-295, KT-474

## Summary
- Preliminary cash ~$850M as of Dec 31, 2024; runway into mid-2027.
- KT-621 Phase 1 healthy volunteer data expected Q2 2025; Phase 1b AD starts Q2 2025 with data Q4 2025.
- KT-295 (TYK2) IND/Phase 1 start Q2 2025; data expected late 2025.
- KT-474 (IRAK4) Phase 2b dose-ranging in HS and AD ongoing, completion expected 1H26 and mid-2026.
- Novel oral immunology program (first-in-class) to be disclosed 1H2025; clinical testing expected early 2026.

## SEC filing metadata
- accession: 0001193125-25-006124
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/0001193125-25-006124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-006124
- JSON: https://secwatch.observer/filing/0001193125-25-006124.json
- Plain text: https://secwatch.observer/filing/0001193125-25-006124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.